Chronic interstitial lung disease in children: Response to high‐dose intravenous methylprednisolone pulses

Abstract

Summary.The prognosis for children with chronic interstitial lung disease is poor and the mortality rate is high, especially in infants. This explains the many therapeutical protocols which have been proposed and investigated by several authors. In the present work, we evaluated the response of three infants with idiopathic pulmonary fibrosis to high-dose intravenous prednisolone pulses. The patients were referred to the department at the age of 4, 17, and 3 months, respectively. The diagnosis was confirmed by open lung biopsy and intravenous pulse methyl prednisolone therapy was started with the following protocol: 300 mg/m 2 methylprednisolone daily for 3 days, repeated every 4 to 6 weeks. Because of the extreme severity of the respiratory distress at the time of diagnosis, the intravenous pulse treatments were initially complemented by oral prednisone. Clinical improvement was noticed within 6 months with progressive correction of hypoxemia. After follow-up for 3.5 to 4 years, with a total number of pulses of 37, 26, and 32, respectively, the children are symptom-free and do not require oxygen supplementation. During this period, no side effects and no adrenal insufficiency could be documented. Based on current knowledge of steroid action, it can be speculated that the response to intermittent high-dose intravenous methylprednisolone may explain the ability of this mode of hormone administration to maintain an adequate level of glucocorticoid receptor expression. More information and trials through multicenter collaborations are needed to assess therapeutical protocols of repeated high-dose intravenous steroid treatment. Pediatr Pulmonol. 1998; 26:332-338.

The impact of receiving genetic test results on general and cancer‐specific psychologic distress among members of an African‐American kindred with a BRCA1 mutation

“…HDPIM therapy was introduced over 30 years ago in the treatment of renal grafts,28 and has since been expanded to treat a variety of immune‐mediated inflammatory diseases especially rheumatologic ones 29. The use of HDPIM in pediatric pulmonology was first described in three infants with severe idiopathic interstitial fibrosis in 19989 resulting in improvement with no side effects including adrenal insufficiency, which is frequently seen after treatment with oral prednisolone. We have used HDPIM as basic regimen in pediatric HP with the same few observations of side effects.…”

Treatment of allergic alveolitis with methylprednisolone pulse therapy

“…From experience with rheumatoid disease, the maximum effect is achieved after 2 weeks. Recently, a series of case reports showed that pulse therapy was effective in interstitial lung diseases in children unresponsive to continuous systemic steroid therapy (9,10). The efficacy was found to be superior to continuous systemic treatments in some reports.…”

Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options

“…HDPM treatment is recommended in other inflammatory lung diseases in children. 75,76 Reported side effects include transient flushing, headache, mood changes 77 and sinus bradycardia, 78 but no serious long-term events have been described in children. HDPM has been the standard treatment of BO since 1999 at our centre, and we here summarise the results.…”